ClinicalTrials.gg
CompletedNCT05337267Updated Aug 21, 2023

Phase I Study of Sintilimab in Healthy Chinese Male Subjects

A Phase 1 interventional study of sintilimab (after the change) and sintilimab (before the change) in Healthy Male Subjects, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Completed at 1 site in China. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-08-21.

Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
117
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

The purpose of this study is to evaluate the pharmacokinetic similarity of sintilimab with different manufacturing process in healthy male subjects. Another purpose is to determine safety, and immunogenicity of sintilimab with different manufacturing process,also to determine Pharmacodynamics of sintilimab with different manufacturing process in 12 healthy male subjects.

02

Conditions studied

  • Healthy Male Subjects
03

In context

Lead sponsor

Innovent Biologics (Suzhou) Co. Ltd. is the lead sponsor of 199 studies on the registry; 46 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males aged 18 to 45 (including both ends);
  2. (BMI) is 19.0\~28.0 kg/m2 (including both ends), and body weight is 62.0\~73.0kg (including both ends);
  3. The investigator is assessed as a healthy male subject based on a complete medical history, including physical examination, vital signs, 12-lead and laboratory tests;
  4. Subjects agree to use reliable measures (such as abstinence, sterilization, contraceptives, injectable contraceptive medroxyprogesterone or subcutaneous implant contraception, etc.) during the study period and within 6 months after the study drug infusion. );
  5. Fully understand the purpose of the trial, understand the pharmacological effects of the study drug and possible adverse reactions; and abide by the trial process and voluntarily sign the .

Exclusion criteria

Exclusion Criteria:

  1. Those with a history of chronic liver, kidney, cardiovascular, neurological/mental, digestive tract, respiratory, urinary, endocrine and other systemic diseases;
  2. Those with a history of diseases (see Annex 1);
  3. Regular drinkers within 6 months prior to screening (regular drinkers are defined as drinking more than 2 units per day on average, or drinking more than 14 units per week on average: 1 unit = 360ml of beer or 45ml of alcohol for 40 % above spirits or 150ml wine);
  4. Subjects who have had opportunistic infections within 6 months before screening (such as: herpes zoster, active cytomegalovirus, Pneumocystis carinii, histoplasma, aspergillus, mycobacteria, etc. );
  5. Known history of recurrent or chronic infection, history of chronic or recurrent infection, including but not limited to: chronic kidney infection, chronic chest infection (such as bronchiectasis), sinusitis, recurrent urinary tract infection, Open, draining or infected skin wounds;
  6. Those with a history of acute infection within 2 weeks before screening;
  7. A history of malignant tumor, unless it is a skin squamous cell carcinoma or basal cell carcinoma that has been successfully resected and has no evidence of ;
  8. Those who are suspected or confirmed to be allergic or have had severe drug or food allergy reactions in the past, have a clear history of allergies and/or are allergic to the study drug or its components after inquiries;
  9. Have used any drugs (including traditional Chinese medicines and vitamins) within 2 weeks before screening, or the last medication is less than 5 half-lives of the drug from the test administration day, whichever is longer;
  10. Those who have used /PD-L1 drugs in the past;
  11. Those who have participated in other interventional clinical trials within 3 months before screening;
  12. Those who lost blood, donated blood or received any blood product transfusion of ≥400 ml within 3 months before screening;
  13. Those who received major surgery or hospitalization due to illness within 3 months before screening;
  14. Those who have been vaccinated with within 6 months before screening, or who are expected to receive live vaccines during the study period;
  15. Those with a history of drug abuse or positive drug screening results within 12 months before screening;
  16. Those with abnormal vital signs and physical examination during the screening period and judged by the research doctor to have clinical significance;
  17. Abnormal (such as >450ms, shortened or prolonged PR interval, second-degree and third-degree atrioventricular block, pre-excitation syndrome, etc.) during the screening period and judged by the research doctor to be ;
  18. Abnormal chest X-ray (frontal and lateral) or lung CT during the screening period and judged by the research doctor to have clinical significance;
  19. Abnormal laboratory tests and clinical significance during the screening period. (Remarks: If there is any abnormality and it has clinical significance as judged by the research doctor, if it is within the normal range after re-examination, it can also be included in the group);
  20. Patients with known history of tuberculosis or suspected clinical manifestations of tuberculosis (including but not limited to pulmonary tuberculosis, lymph node tuberculosis, tuberculous pleurisy, etc.), positive test for tuberculosis laboratory test (QuantiFERON-TB tuberculosis test/T.SPOT tuberculosis test) examinee;
  21. (HIV) antibody, virus (HCV) antibody, syphilis test (RPR), virus (HBV) surface antigen, e antigen ( Positive results for either HBeAg) or core antibody (HBcAb);
  22. Subjects who have a reproductive plan from the screening period to 6 months after the administration of the study drug, or who are unwilling to take the measures specified in the protocol during the trial;
  23. The investigator believes that it is not suitable to participate in this clinical trial due to other reasons.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
117 participants (actual)

Study arms

  • Experimental
    sintilimab (after the change)

    Drug: sintilimab (before the change)

  • Active comparator
    sintilimab (before the change)

    Drug: sintilimab (after the change)

Interventions

06

What researchers measure

Primary outcomes

  1. Pre-experiment: Treatment-emergent Adverse Events (TEAEs) graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI-CTCAE v5.0) incidence.

    Time frame: Day 43

  2. Pre-experiment: Serious Adverse Events (SAEs) graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI-CTCAE v5.0) incidence.

    Time frame: Day 43

  3. Formal test: Bioequivalence results using the area under the plasma concentration-time curve (AUC0-inf) as the judging indicators.

    Time frame: Day 57

  4. Bioequivalence results using the peak serum drug concentration (Cmax) as the judging indicators.

    Time frame: Day 57

Secondary outcomes

  1. Other PK parameters: Area under the plasma concentration-time curve (AUClast)

    Time frame: Day 57

  2. Other PK parameters: Volume of distribution (V)

    Time frame: Day 57

  3. Other PK parameters: Clearance (CL) .

    Time frame: Day 57

  4. Other PK parameters: Half-life (t1/2). Other PK parameters, including but not limited to elimination half-life (t1/2).

    Time frame: Day 57

  5. The occurrence of Neutralizing antibodies Antibody(NAb)

    Time frame: Day 57

  6. The occurrence of Anti-drug Antibody(ADA)

    Time frame: Day 57

  7. PD indicator: PD-1 receptor occupancy rate.

    Time frame: Day 57

07

Study locations

1 site
  • Hunan Cancer Hospital
    Changsha, Hunan 410006, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2022 to primary completion in May 2023, 13 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 22, 2022
First posted
Apr 20, 2022
StartActual
Apr 13, 2022
Primary completionActual
May 24, 2023
CompletionActual
Jul 24, 2023
Last update
Aug 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05337267
Responsible party
Sponsor
First posted
Apr 20, 2022
Start date
Apr 13, 2022
Primary completion
May 24, 2023
Completion
Jul 24, 2023
Last update
Aug 21, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sintilimab

Start the discussion